Reference
Hou Z, et al. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation. Oncologist 28: 449-452, No. 5, May 2023. Available from: URL: http://doi.org/10.1093/oncolo/oyac280
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1971, 34 (2023). https://doi.org/10.1007/s40278-023-45159-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-45159-0